Aventis has announced the signing of a commercial research, option and license agreement with Vivalis in the field of avian stem cells. The two companies will combine the ALVAC canarypox virus platform of Aventis Pasteur, the vaccines business of Aventis, and Vivalis’ proprietary avian stem cell platform to enable Aventis Pasteur to improve the large-scale Read more about Vivalis And Aventis Sign License Agreement[…]
American Home Products Corporation and Aventis Pharma have renegotiated their licensing agreement for trimegestone, a modern progestational molecule originated by Aventis for hormone replacement therapy. Under the new agreement, Wyeth-Ayerst Laboratories, the pharmaceutical division of AHP, has exclusive development and worldwide marketing rights for trimegestone for all indications and formulations except transdermal products. The rights Read more about AHP And Aventis Pharma Finalise HRT Agreement[…]